Expanding TAVR to Low-Risk Patients: What Changed in 2025
Transcatheter aortic valve replacement used to be reserved for high-risk surgical candidates. The evidence base for low-risk TAVR has matured. Here is what that means for patients at Aster.
The evolution of evidence
The PARTNER 3 and Evolut Low Risk trials established non-inferiority of TAVR versus surgery for low-risk patients with severe aortic stenosis. Five-year follow-up data, published in late 2024 and 2025, confirms that TAVR outcomes remain comparable to surgical aortic valve replacement in appropriately selected low-risk patients.
How we select patients
Every TAVR candidate at Aster is reviewed by our valve team, which includes interventional cardiology, cardiothoracic surgery, imaging, and anesthesia. We consider anatomy, frailty, life expectancy, and patient preferences. Not every low-risk patient is a TAVR candidate, and not every high-risk patient is a surgical candidate. The right decision is case-specific.
Our five-year TAVR outcomes
From 2020 through 2025, Aster performed 1,180 TAVR procedures. 30-day mortality: 1.1%. Stroke rate: 1.3%. New permanent pacemaker rate: 9.8%. Median length of stay: 2 days. These outcomes are consistent with national benchmark data from the TVT Registry.
What's next
The next frontier is TAVR for younger patients with bicuspid anatomy, and durability data beyond 10 years. Both questions are under active investigation in trials we participate in. We will publish updated outcome data annually.
New patients seen within 5 business days.
Our patient navigation team triages every new request, verifies insurance, and matches you to the right specialist.